Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Novo Nordisk A/S
NOVANovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Address: Novo Alle 1, Bagsvaerd, Denmark, 2880
Analytics
Zielpreis von Wall Street
148.23 USDKGV
43.5503Dividendenrendite
1.11 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen NOVA
Dividenden-Analyse NOVA
Dividendenwachstum über 5 Jahre
62 %Kontinuierliches Wachstum
5 JahreAusschüttungsquote 5-Jahres-Durchschnitt
19 %Verlauf der Dividende NOVA
Bewertung der Aktie NOVA
Finanzen NOVA
Ergebnisse | 2019 | Dynamik |